NFE2L2 and hepatocellular carcinoma: Upregulated PIP5K1A competes with NRF2 for KEAP1 binding, which decreases the ubiquitination degradation of NRF2 and promotes its nuclear translocation, thereby suppressing ferroptosis, and ultimately driving hepatocellular carcinoma (HCC) tumorigeneses and sorafenib resistance.